Webinars

Immuno-oncology (IO) is a rapidly developing therapeutic approach, which harnesses the precision of the immune system, to allow for a targeted approach in the killing of cancer cells, whilst sparing healthy cells.

Organoids contain multiple organ-specific cell types that are spatially grouped together to replicate an organ and/or express an organ’s specific aspects or functions, such as neural activity, contraction, endocrine section, excretion and filtration.

Immuno-oncology (IO) has transformed cancer treatment. The number of treatments in the IO pipeline continues to increase. If the treatment is CAR-T cells, adoptive T cell therapy or checkpoint inhibitors, the mechanism of action includes T cell lysis of tumor cells.

Genome-wide association studies have identified genetic associations between multiple immune genes (e.g. TREM2, CD33) and Alzheimer’s disease (AD), highlighting a role for neuroinflammation in dementia.

A principal barrier to treatment of pancreatic cancer is the densely fibrotic tumor microenvironment, its high interstitial pressure acts to collapse blood vessels and impair the delivery of chemotherapy.

The Endoplasmic Reticulum (ER), a network of membranous sheets and pipes, supports functions encompassing biogenesis of secretory proteins and delivery of functional solutes throughout the cell periphery.

Immunotherapy, to help patients’ own immune systems target and kill cancerous cells, while sparing their healthy cells, requires a deep understanding of T cell biology.

Neoantigens resulting from the presentation of mutated peptides on MHC molecules are attractive therapeutic targets.

Metabolic reprogramming is a hallmark of cancer, and it supports the increased energetic, biosynthetic, and redox demands associated with tumor development and progression.

Traditional 2D cultures don’t really represent how cells function in the body. When cells are grown flat, in monolayers, on plastic, they lack the cellular context they would normally get in vivo.

Over the last decade, 3D cell culture has become more widely used, because compared to 2D cell culture, it better represents in vivo tissue...

Researchers are better able to recapitulate the in vivo cell environment within the lab setting now, thanks to new innovations in cell source, manipulation, and assay readout...

Technological advances are driving rapid progress in disease areas such as oncology, immuno-oncology and neuroscience, revealing new treatment...

Various in vitro cell culture assays have been used for decades to evaluate disease pathology and uncover potential therapeutic treatments. Despite many successes with these models, they have critical shortcomings. Growing evidence suggests that models providing more predictive and translational observations are desperately needed.

JoVE VIDEO JOURNAL (Exclusive access): A Simple Migration/Invasion Workflow Using an Automated Live-cell Imager

Gene therapy recently gained momentum as a promising anticancer strategy. Successful gene therapy relies on, but is not restricted to, delivering the right dose, at the right time, at the right place. Accordingly, addressing gene therapy efficacy and specificity in real-time is pivotal for the success of preclinical programs in this field of research.

Real-time analysis of cellular phagocytosis; characterisation of anti-CD47 antibodies as potential novel immuno-therapies

This informative and practical webinar will guide and train you through the whole workflow process of setting up an assay, from harvesting cells, manipulating plates to analysing data and conducting kinetic assays using the integrated software.

It is increasingly appreciated that crosstalk at the nexus of the nervous and immune systems mediates a delicate balance between dysregulation and homeostasis across many important biological processes. In this Cell Press webinar, three speakers will explore emerging developments in our understanding of mediators and mechanisms of neuro-immune interplay.

This event offers an overview of how live-cell analysis enables real-time analysis for the full workflow of the cells.

How do your immunotherapeutic cells kill a tumour? Laboratory assessment of T cell killing efficiency is debatable: either too artificial or too murine systems. Although not perfect, live cell imaging possesses the advantage to record the event live in a quantifiable manner.

Gain insights from an assay development expert as Dr. David Baker of AstraZeneca, discusses how you can enable rapid measurement of cell proliferation, transfection efficiency, cell confluence and other using live-cell imaging and advanced high throughput flow cytometry.

In this webinar, Del Trezise will review live-cell analysis techniques and the most recent developments in the field. Advances will be illustrated with examples drawn from 3D oncology co-culture applications, antibody-based cell identification methods, and cell-by-cell analysis to probe immune cell heterogeneity and subsets.

During this webcast Dr. Mayumi Fujita of the National Institutes for Quantum and Radiological Science and Technology in Japan will address the method of real-time imaging of invading cells using the IncuCyte Live-Cell Analysis System, and describe how this model is useful for many studies.

Our new cell-by-cell analysis module allows users to ‘count and classify’ heterogeneity in cell populations over time. This software uses novel algorithms to segment the HD phase-contrast images which facilitates (1) label-free true cell counting (2) extraction of basic morphological features of individual cells (e.g. size, shape), and (3) measurement of fluorescence intensity that originates from within each cell (‘fluorescence within a phase boundary’). The ability to analyse at a cell-by-cell level will enable the characterisation of subsets and the power to monitor these individual groups in their response to various stimuli.

The success of immune checkpoint blockade adds new therapeutic category to Cancers are the most heterogenous group of diseases affecting humans. Multiple compensating pathways work to promote disease progression. Various immunotherapies have shown anticancer promise, but the their targeted nature limits the scope of their action and applicability.

In the search for greater clinical translation, cancer researchers are increasingly turning to more complex live-cell assay systems that recapitulate key aspects of the tumor microenvironment. These include (1) more relevant tissue organization, (2) bio-matrices containing structural proteins and growth factors, and (3) the presence of stromal and immune cells. In this webinar, we describe integrated protocols and live-cell analysis solutions for different 3D tumor models, ranging from simple mono-culture single spheroid assays through to multi-spheroid tumor/fibroblast and tumor/immune cell co-cultures in a Matrigel biomatrix.

Monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs) are widely used biological therapeutics. A key property of these biologics is the extent and rate of internalization into different cells, which governs their efficacy, safety and pharmaco-dynamic profile. As a result, quantifying and comparing the rate of Ab internalization of drug candidates is critical in the biopharmaceutical selection and optimization process.

Learn how to easily optimize culture conditions for (hiPSC)-derived neurons, real-time live-cell analysis using phase (monoculture) or fluorescent (co-culture) NeuroTrack software can be used to visualize and quantify neurite dynamics, other live-cell phenotypic assays (e.g. apoptosis) are used to monitor neuronal cell health and validate mechanisms of action

Despite efforts made on research of cancer cell and immune cell interaction, how cancer cells initiate immune escape is less understood. Dr. Chia-Wei Li reveals PD-L1’s immunosuppression activity is stringently modulated by the spatial restraints between ubiquitination and N-linked glycosylation. Together, his results link ubiquitination and glycosylation pathways with stringent regulation of PD-L1, proposing a new therapeutic strategy to enhance cancer immune therapy efficacy.

Watch to Dr. Daniel Appledorn, PhD discuss live cell assay approaches for immunology and immuno-oncology including cell health, chemotaxis, immune cell killing, and more at AAI 2017.

Deriving deeper biological insight & improving productivity in immune-cell biology

Learn long-term live cell imaging for high-content applications & learn about the new developments in image acquisition that combine live cell incubation and imaging with high-content screening approaches.

Smart Cell Assays for Immuno-Oncology

Furthering Insight and Productivity in Cell Biology with Real-Time Quantitative Live-Cell Analysis

2016 IncuCyte® Live-Cell Analysis Webcasts: Smart Cell Monitoring & Analysis